NOTES ON ABSTRACT PREPARATION

1. All presentations must be of original work.
2. Abstracts must be prepared in English.
3. The original abstract plus two copies must be received by the Conference Secretariat on or before 31 January 2001.
4. Abstracts must be submitted on the Abstract Form provided. Faxes will be accepted provided the original is received within one week.
5. Abstracts will appear exactly as submitted.
6. Upon receipt, abstracts will be submitted to the Scientific Committee for review. The Scientific Committee reserves the right to select the abstracts for oral or poster presentation.
7. Presenting authors whose abstracts are accepted for presentation must register for the meeting and pay the required fee by 10 February 2001.
8. Accepted abstracts will be published in The Aging Male, the official journal of the International Society for the Study of the Aging Male (ISSAM).
9. Oral Presentations - The paper must be presented in 10 minutes.
10. Use standard abbreviations and place unusual ones in parentheses after the word first appears. Do not use abbreviations in the title.
11. The title should contain the major key words of the presentation to aid in communicating its central emphasis.
12.

Guidelines The text of the abstract should briefly state :

Objective(s): indicate the purpose of the study or the hypothesis that was tested.
Design & Method: include the setting for the study, the subjects (number and type), the diagnosis or intervention, and type of statistical analysis. If references are needed, they should be given in the text.
Results: present as clearly as possible the outcome of the study and statistical significance if appropriate.
Conclusions: briefly discuss the data and emphasize the significance of the results.

TYPING INSTRUCTIONS

1. Type the abstract in small letters entirely within the frame so that the resulting rectangle is vertical (height: <107 mm, width: <170 mm). Computer-generated abstracts will only be accepted on a separate sheet if the total type area is within the given dimensions.
2. Type the title of the abstract in bold in upper and lower case on the first line.
3. Write the name(s) of author(s) with initials preceding the last name, institution(s), city and country as shown in the sample abstract. Utilize a maximum of five lines. Underline the name of the presenting author only.
4. Double-space between the heading and the text of the abstract.
5. Type the text single-space with no paragraphs or indentations, using the full width of the form.
6. Abstracts should be clearly typed using a high-contrast type (a dot matrix printer is not acceptable).
7. Avoid corrections, errors and misspellings.
8. Since abstracts are printed in camera-ready form, i.e. reproduced exactly as submitted, please proofread carefully.
9. Please do not fold the typewritten area.
 

 

Note: For abstract submission via email attachment of the downloaded abstract form, some of the above instructions may not apply.

 
Download abstract submission form in MS Word format

 

SAMPLE ABSTRACT DEADLINE FOR ABSTRACT SUBMISSION : 31 January 2001

Hormone replacement therapy : prevalence, compliance and the 'healthy women' notion

A.H. MacLennan, D.H, Wilson* and A.W. Taylor*
Department of Obstetrics and Gynaecology, University of Adelaide; and *Behavioural Epidemiology Unit, Public and Environmental Health Service, South Australian Health Commission, Adelaide, South Australia

Objectives The objective of this study was to assess the current trends of hormone replacement therapy (HRT) use, including rates of use, length of use, continuation rates and characteristics of users and non-users and to examine the hypothesis that 'healthy women' are more likely to be users of HRT. Design and methods Analysis was carried Out of three representative South Australia's population studies in 1991, 1993 and 1995 comprising 3019, 3004 and 3016 personal interviews, respectively. Results Current use (and ever-use) of HRT in all women aged 50 years and over rose from 13.2% (26.7%) in 1991, to 21.2% (31.9%) in 1993 and 26.0% (40.5%) in 1995. Highest use is now in the 55-59 year age group where, in 1995, current use was 50.9% and ever-use was 69.0%. Median compliance rates with HRT rose from 24 months in 1991 to 60 months in 1995 for current users age 50 years old age or above. The pattern of increasing use of HRT is not consistent across age groups. Analysis of the 1995 data show that, in contrast with increasing rates of current use in women over 55 years, there was no overall change in rates for women below this age. There were no statistically significant differences in health indicators, e.g. blood pressure, smoking, cholesterol level or body mass index between users and non-users of HRT. However, users reported significantly higher rates of previous osteoporosis and hysterectomy. Conclusions Prevalence rates of HRT use are increasing together with compliance rates and this may reflect increased confidence with HRT therapy. Users of HRT have an increased rate of mammography compared to non-users and this may contribute to earlier detection and, therefore, increased estimates of breast cancer in HRT users. There was no support from the 1995 data for a 'healthy women' hypothesis among HRT users.

 
SAMPLE ABSTRACT DEADLINE FOR ABSTRACT SUBMISSION : 31 January 2001

 

 

[ ISSAM Table of Contents | Home ]